Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProtEx
- Development stage
- Preclinical
- Lead developer
- ExoNavis Therapeutics
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
ProtEx is an exosome-based drug delivery platform developed by ExoNavis Therapeutics. It utilizes extracellular vesicles (exosomes) to deliver therapeutic payloads to specific target tissues, aiming to improve the pharmacokinetic profile and targeted delivery of various treatments. The platform is currently being explored for the treatment of respiratory diseases, specifically Acute Respiratory Distress Syndrome (ARDS) and Chronic Obstructive Pulmonary Disease (COPD). As a delivery technology, it represents a platform-level approach rather than a single molecular target therapy, designed to enhance the efficacy and safety of therapeutic agents in the lungs.
Beyond the preview
Go deeper on ProtEx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProtEx.